Abstract 887P
Background
Locally advanced laryngeal carcinoma is treated by concomitant chemotherapy and radiotherapy then surgery whenever possible. Most patients between 60-70 years refuse surgery, therefore, we designed a treatment in order to postpone or evade the surgical option in elderly patients with T3 and T4 disease.
Methods
In this prospective phase II trial, we included 120 patients diagnosed with locally advanced laryngeal carcinoma (84 patients with T3 disease versus 36 patients with T4 disease) aged between (60-74 years) 67 years in median. Study was started by weekly paclitaxel at a fixed dose of 150mg and carboplatin AUC4 taken on days 1,8 and 15 of a 21-day schedule, cycles were repeated for 6 times. Then patients were evaluated by CT scan and laryngoscopy. Complete responders, partial and non-responders are referred to concomitant radiotherapy (60 Gy) with weekly cisplatin at 50mg for 6 weeks. Patients were followed up for a median of 42 months (38-57 months). Study end point was objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) for 3 years. Secondary end point was toxicity profile.
Results
ORR was observed in 116 patients (96.6%) evaluated by clinical exam, CT scan and laryngoscopy. Complete clinical response was documented in 87 patients after completion of chemotherapy 72.5% (95% CI: 66.2-79.1) and 27.5% partial responders (95% CI: 23.4-31.7). At 3 years of follow-up, PFS was 95% (95% CI: 92.7-98.8) (p value 0.001) while the OS at 3 years was 95%. We have lost 4 patients who died after hospitalization for severe neutropenia and renal failure. Surgery was deleted as an option in this category of patients. The toxicity profile was composed of different grades of neutropenia/thrombocytopenia and anemia. Reversable acute renal failure was seen in 5 patients as well as alopecia. Peripheral neuropathy with different grades was documented in 92 patients.
Conclusions
Neoadjuvant chemotherapy followed by concomitant chemo-radiotherapy in the light of feasibility and acceptable toxicity profile can be a substitution for surgery in elderly patients with locally advanced laryngeal carcinoma taking into consideration the good tolerance and the modest toxicity profile.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received anyfunding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
869P - Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab (D) combined with weekly paclitaxel carboplatin in 1st-line in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible to cisplatin
Presenter: Jérome Fayette
Session: Poster session 02
870P - POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients of performance status 2 with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)
Presenter: Martin Forster
Session: Poster session 02
871P - Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC study
Presenter: Lara Iglesias Docampo
Session: Poster session 02
873P - Nivolumab (NIVO) in the first-line (1L) or second-line (2L) and later (2L+) settings in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from the German non-interventional study (NIS), HANNA
Presenter: Andreas Dietz
Session: Poster session 02
874P - Preliminary outcomes from a phase Ib/II study of WX390 combined with toripalimab in patients with recurrent or metastatic head and neck squamous cell carcinoma
Presenter: Ye Guo
Session: Poster session 02
875P - A phase II clinical trial of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Presenter: Dongmei Ji
Session: Poster session 02
876P - Evaluation of the safety and efficacy of ivonescimab in combination with ligufalimab as first-line (1L) treatment for PD-L1 positive recurrent/metastasis head and neck squamous cell carcinoma (R/M HNSCC)
Presenter: Xiaozhong Chen
Session: Poster session 02
878P - Final results of a phase II study of peltopepimut-S and cemiplimab in patients with relapsed/metastatic HPV16+ oropharyngeal cancer that progressed with prior anti-PD-1 therapy
Presenter: Anthony Kong
Session: Poster session 02